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Abstract: With over 50 million currently confirmed cases worldwide, including more than 1.3 million
deaths, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has a major
impact on the economy and health care system. Currently, limited prophylactic or therapeutic
intervention options are available against SARS-CoV-2. In this study, 400 compounds from the
antimicrobial “pandemic response box” library were screened for inhibiting properties against
SARS-CoV-2. An initial screen on Vero E6 cells identified five compounds that inhibited SARS-CoV-2
replication. However, validation of the selected hits in a human lung cell line highlighted that
only a single compound, namely Retro-2.1, efficiently inhibited SARS-CoV-2 replication. Additional
analysis revealed that the antiviral activity of Retro-2.1 occurs at a post-entry stage of the viral
replication cycle. Combined, these data demonstrate that stringent in vitro screening of preselected
compounds in multiple cell lines refines the rapid identification of new potential antiviral candidate
drugs targeting SARS-CoV-2.
Keywords: pandemic response box; drug repurposing; compound screen; SARS-CoV-2; Retro-2.1;
remdesivir; Vero E6; Calu-3
1. Introduction
In December 2019, a new zoonotic coronavirus emerged in Wuhan, Hubei province, China,
named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the etiological agent
of coronavirus disease 2019 (COVID-19) [1–3]. The clinical features of SARS-CoV-2-infected patients
range from mild cold-like symptoms to severe illness ultimately leading to acute respiratory distress
syndrome [2,4]. Patients at an older age and with underlying comorbidities are at higher risk of
developing severe courses of COVID-19 [5]. Despite unprecedented international public health
response measures to contain SARS-CoV-2 transmissions, the viral outbreak is currently categorized
as a pandemic with over 50 million confirmed laboratory cases reported worldwide, including over
1.3 million deaths as of November 2020 [6]. At present, and despite earlier outbreaks of SARS-CoV
and Middle East respiratory syndrome (MERS)-CoV, there are limited approved antiviral treatment
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options, such as antiviral drugs, vaccines and immuno-prophylaxis, that can be used prophylactically
or therapeutically to halt the current SARS-CoV-2 infections.
Vaccine development is a long process to reach approvement for clinical use, and although
SARS-CoV-2 vaccine developments are currently expedited, the eventual worldwide vaccine
distribution may be delayed for additional months [7]. Moreover, while vaccines are used
prophylactically, antiviral drugs can be employed both prophylactically and therapeutically.
For SARS-CoV-2, several antiviral compounds have been evaluated, such as the nucleoside analogue
remdesivir, the transmembrane serine protease 2 (TMPRSS2)inhibitor camostat mesylate, and the
antimalaria drug (hydroxy-) chloroquine, targeting different stages of the viral replication cycle [8–10].
All three antiviral drugs have recently been tested in large patient cohorts, whereby remdesivir has been
shown to reduce the hospitalization time, but proved to exert only a marginal benefit for patients with
severe COVID-19 disease [11]. Several clinical trials with either hydroxychloroquine or chloroquine
did not reveal any benefit in the clinical outcome [11–15]. Additionally, RNA viruses, including
coronaviruses, are known to rapidly evade antiviral drug inhibition by developing resistance mutations
and subsequent selection of drug-resistant viral populations [16–18]. Therefore, the use of multiple
drug regimens as well as expanding the repertoire of available antiviral treatment options are of crucial
importance to combat the SARS-CoV-2 pandemic.
Since the beginning of the 21st century, multiple epidemics have been caused by a viral
or bacterial agent, such as the Ebola-, measles-, Zika-viruses and cholera [19]. Some epidemics
have even reached pandemic proportions, such as the influenza A/H1N1 virus and the currently
circulating SARS-CoV-2 [20,21]. As a rapid response to these virulent agents, the Medicines for
Malaria Venture and Drugs for Neglected Diseases initiatives developed the pandemic response box
(PRB), a compound library containing 400 compounds with antibacterial, antifungal and antiviral
properties. This compound library allows rapid evaluation of potential drug repurposing against
newly emerging pathogens.
To this end, we performed an in vitro-based screen of 400 preselected compounds with antibacterial,
antifungal, and antiviral properties contained in the PRB and assessed their antiviral activity against
SARS-CoV-2. A stringent large-scale screen in Vero E6 cells highlighted sixteen compounds that
prevented virus-induced cytopathogenic effects (CPE) while displaying low cytotoxicity and no
detrimental effect on cell viability. Further validation using Vero E6 and Calu-3 cells revealed that only
one compound, Retro-2.1, showed substantial SARS-CoV-2 inhibition while the antiviral effects of
the other compounds were only observed in Vero E6 cells. Time-of-addition analysis indicated that
Retro-2.1 targets SARS-CoV-2 at a post-entry stage of the viral replication cycle. Together, these data
demonstrate that stringent in vitro screening of preselected compounds on different cell lines refines
the rapid identification of a new potential antiviral candidate drugs targeting SARS-CoV-2.
2. Materials and Methods
2.1. Cell Lines and Viruses
Vero E6 cells (kindly provided by M. Müller and C. Drosten, Charité, Berlin, Germany)
and Calu-3 cells (HTB-55, American Type Culture Collection (ATCC), Manassas, VA, USA)
were propagated in Dulbecco’s modified Eagle Medium–GlutaMAX, 10% (v/v) heat-inactivated
fetal bovine serum, 100 mg/mL streptomycin, 100 IU/mL penicillin, 1% (w/v) non-essential
amino acids and 15 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, Gibco,
Gaithersburg, MD, USA). Cells were maintained at 37 ◦C in a humidified incubator with 5%
CO2. SARS-CoV-2 (SARS-CoV-2/München-1.1/2020/929 [22]) stocks were produced on Vero E6 cells,
aliquoted and stored at−80 ◦C. Viral titers were determined by tissue culture infectious dose 50 (TCID50)
on Vero E6 cells after 72 h incubation at 37 ◦C in a humidified incubator with 5% CO2.
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2.2. Compound Preparation of the Pandemic Response Box
All 400 compounds (purity of >90%) distributed in 96-well plates were dissolved and diluted
in dimethyl sulfoxide (DMSO, Sigma-Aldrich, St. Louis, MO, USA) and aliquoted at a concentration
of 1 mM in 96-well plates (Techno Plastic Products AG, Trasadingen, Switzerland) and were kept
at −20 ◦C until further use. Compounds were diluted at the indicated concentration in cell culture
medium. The control compound remdesivir (MedChem Express, NJ, USA, HY-104077) was diluted
to a 20 mM working stock in DMSO and stored at −80 ◦C, while K22 was prepared and stored as
described previously [17].
2.3. Antiviral Activity Screening
Vero E6 cells were seeded in 96-well clear bottom, black wall plates (Costar, Tewksbury, MA, USA),
at a density of 20,000 cells per well, one day prior to the experiment. Cells were pretreated for 2 h with
1 µM of each compound contained in the PRB. Remdesivir [8], K22 [17], and vehicle controls (DMSO)
were included in each plate. Subsequently, cells were infected with SARS-CoV-2 at a multiplicity
of infection (MOI) of 0.01 in compound-containing medium and incubated at 37 ◦C in a humidified
incubator with 5% CO2. Uninfected (mock) controls were included in each plate. At 48 h post-infection
(hpi), cells were fixed with 4% (v/v) neutral buffered formalin (Formafix AG, Hittnau, Switzerland)
and stained with crystal violet. Cell viability and cytotoxicity were assessed in parallel, in identically
treated, uninfected plates. Two independent experiments were performed, each including a technical
duplicate. Wells containing an intact cell layer without apparent CPE after infection and displaying
high cell viability and low cytotoxicity were considered as hits.
2.4. Cell Cytotoxicity and Cell Viability
Cell cytotoxicity and viability were assessed using CellTox™ green cytotoxicity assay (Promega,
Dübendorf, Switzerland) and CellTiter-Glo®2.0 assay (Promega), respectively, according to
manufacturer’s protocols. Readout was performed on a Cytation 5 Cell Imaging Multi-Mode Reader
(BioTek, Sursee, Switzerland). The mean raw values were standardized by calculating the z-scores and
individual cell cytotoxicity and viability scores of compounds exceeding a confidence interval of 95%
(z-score of −2 or +2) were regarded as nonviable hits.
2.5. Half Maximal Effective Concentration (EC50) Determination of Selected Compounds
Vero E6 and Calu-3 cells were seeded in 96-well clear bottom, black wall plates (Costar), at a
density of 20,000 or 40,000 cells per well, respectively, one day prior to the experiment. Cells were
pretreated for 2 h with 2-fold serial dilutions of selected compounds, ranging from 4 µM to 0.062 µM.
Cells were infected with SARS-CoV-2 (MOI of 0.01) in compound-containing medium and incubated at
37 ◦C in a humidified incubator with 5% CO2. Cells were fixed with 4% (v/v) neutral buffered formalin
at 24 and 48 (Vero E6) or 48 (Calu-3) hours post-infection and processed for immunofluorescence
analysis. Briefly, cells were permeabilized with 0.1% (v/v) Triton X-100 (Merck, Kenilworth, NJ, USA)
for 5 min and blocked in phosphate-buffered saline (PBS), supplemented with 50 mM NH4Cl,
0.1% (w/v) saponin (Sigma) and 2% (w/v) bovine serum albumin (Immunoglobulin G (IgG)-free, Jackson
Immunoresearch, Westgrove, PA, USA). SARS-CoV-2 antigen-positive cells were detected using a
rabbit polyclonal anti-SARS-CoV nucleocapsid protein (Rockland, Limerick, PA, USA 200-401-A50)
and a secondary Alexa Fluor® 488-labeled donkey anti-rabbit IgG (H + L) or Alexa Fluor® 647-labeled
donkey anti-rabbit IgG (H + L) (Jackson Immunoresearch). Samples were counterstained using
4′,6-diamidino-2-phenylindole (DAPI, Thermo Fisher Scientific, Darmstadt, Germany) to visualize the
nuclei and finally washed with PBS.
Images were acquired on a Cytation 5 Cell Imaging Multi-Mode Reader (BioTek) equipped
with a 4× air objective (numerical aperture: 0.13). Four images per well were acquired to cover the
entire surface of the well and processed and stitched using the Gen5 ImagePrime software package
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(v. 3.08.01). The percentage of virus-infected cells in each well was calculated by dividing the number
of cells with a cytoplasmic green fluorescent protein (GFP) signal (SARS-CoV nucleocapsid) by the
total number of detected cells (DAPI). Nuclei were segmented using a primary mask with dynamic
thresholding and a secondary mask encompassing the cytoplasm was based on the primary mask,
dilated by 5 µm. The half maximal effective concentration (EC50) was calculated in GraphPad
Prism (San Diego, CA, USA, v. 9.0.0) using the non-linear variable slope with four parameters option,
the corresponding EC90-value was calculated based on the previously calculated EC50-value and the
hill slope values.
2.6. Half-Maximum Cytotoxicity Concentration (CC50) Determination
To determine the cytotoxicity of the compounds and for later calculation of the selectivity index
(SI), a dilution series ranging from 100 µM to 0.19 µM for both Vero E6 cells and Calu-3 cells was
prepared in cell culture medium and incubated for 48 h at 37 ◦C in a humidified incubator with 5% CO2.
Cytotoxicity and cell viability were both assessed as described earlier, whereby the CC50 was calculated
in GraphPad Prism (v. 9.0.0) using the non-linear variable slope with four parameters option.
2.7. Time-of-Addition Experiment
Vero E6 cells were seeded in 96-well, clear bottom, black wall plates (Costar) at a density of
20,000 cells per well. Retro-2.1 and the vehicle control (DMSO) were diluted in cell culture medium at
a concentration of 10 µM or using an equal volume of DMSO. Cells were (pre-) treated and infected
with a MOI of 0.01. Following each incubation step, cells were washed three times with PBS to
remove any residual compound or virus. At 24 h post-infection, supernatant was collected for viral
titration, while cells were fixed and processed for immunofluorescence analysis as described before
using an Alexa Fluor® 647-labeled donkey anti-rabbit IgG (H + L) as a secondary antibody (Jackson
Immunoresearch).
2.8. Data Representation
Graphs were generated using GraphPad Prism software (v. 9.0.0) and the final figures were
assembled in Adobe Illustrator CS6 (v. 16.0.0). Brightness and contrast of microscopy pictures were
minimally adjusted and processed identically to their corresponding control using FIJI (v. 1.53c).
Images were assembled using the FigureJ plugin in FIJI [23].
3. Results
3.1. Survival Screen with Compounds Included in the Pandemic Response Box against SARS-CoV-2
To identify potential antiviral compounds against SARS-CoV-2 replication, 201 antibacterial,
46 antifungal and 153 antiviral molecules included in the PRB were screened using a conservative
concentration of 1 µM. Based on the documented inhibition of coronavirus replication, remdesivir
was included as a positive control [8]. The compound K22 was also included in the analysis since it
has been shown to inhibit a broad range of viruses including coronaviruses, arteriviruses, toroviruses
as well as different members of the family Flaviviridae [17,24,25]. Vero E6 cells were pretreated
for 2 h and subsequently infected with SARS-CoV-2 (MOI of 0.01) for 48 h in drug-containing
medium. Cell survival was scored from 0 (virus-induced cytopathogenic effects; CPE) to 1 (no CPE),
upon evaluation of SARS-CoV-2-induced CPE using crystal violet staining (Figure 1A). The cytotoxicity
and cell viability were assessed on uninfected plates processed in parallel, to exclude detrimental
effects of the compounds on the cells.
This survival screen resulted in a total of seventeen compounds that inhibited SARS-CoV-2-induced
CPE (red). In parallel, cell viability and cell cytotoxicity assays were performed to exclude detrimental
effects of each compound on the cells. The mean raw values were standardized by calculating the
individual cell cytotoxicity and viability z-scores. Compounds exceeding a 95% confidence interval
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(z-score of −2 or +2) were regarded as nonviable hits. This showed that only a single compound
caused significant cytotoxicity (Plate D, G11; z-score 3.12) (Figure 1B). In contrast, 10 compounds
exceeded the cell viability cutoff, including the previously identified compound in Plate B, D10 (z-score:
−6.498) (Figure 1C). Of note, this compound was also observed as a positive hit in the survival screen,
but due to its impaired cell viability, it was excluded from further analysis. The sixteen remaining hit
compounds are categorized as antifungal (three), antibacterial (six) and antiviral (seven) compounds
(Appendix A), which, similarly to their vehicle control (DMSO) and remdesivir, did not influence
cell cytotoxicity and cell viability. Interestingly, K22 did not show any inhibitory activity against
SARS-CoV-2 at a concentration of 1 µM. These results highlight the relevance of a conservative and
rapid screening of libraries containing compounds that could potentially inhibit SARS-CoV-2.
Figure 1. Cell survival upon infection with severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) (A), cytotoxicity (B) and viability (C) after incubation with pandemic response
box compounds. The survival, cytotoxicity and viability were measured after 48 h of incubation on
Vero-E6 cells at 37 ◦C in a humidified incubator with 5% CO2. The heatmap shows the position on
the plates where survival was observed with a multiplicity of infection (MOI) of 0.01, which was
scored from 0 to 1 (0 = cytopathogenic effects (CPE) and 1 = no CPE) (A). Calculated z-scores of
each individual compound for cell cytotoxicity (B) and cell viability (C). A confidence interval of 95%
(z-score of −2 or +2) was used as cutoff values, which are indicated with gray dashed lines. Each bar
represents an individual compound sorted from high to low z-scores (x-axis). The red bars indicate the
compounds that showed inhibition of SARS-CoV-2 during the survival screen. Results are shown as
mean of two individual experiments performed in two technical replicates.
3.2. Antiviral Efficacy against SARS-CoV-2
To further confirm and evaluate the extent of antiviral activity of the previously highlighted
sixteen compounds, cells were pretreated with the selected compounds at concentrations ranging
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from 4 µM to 0.062 µM and infected with SARS-CoV-2 (MOI of 0.01). After 24 of infection, cells were
fixed and processed for immunofluorescence analysis using the anti-SARS-CoV nucleocapsid protein
antibody and DAPI (Figure 2).
Figure 2. Assessment of the antiviral efficiency by immunofluorescence. To determine the efficiency of
inhibition of each specific compound from the survival screen, a two-fold dilution series ranging from
4 µM to 0.062 µM was prepared following infection with SARS-CoV-2. Vero E6 cells were pretreated
with the compound 2 h prior to infection with SARS-CoV-2 (MOI of 0.01) at 37 ◦C in a humidified
incubator with 5% CO2. Cells were fixed 24 h post-infection, followed by immunostaining with the
cross-reactive SARS-CoV nucleoprotein antigen (SARS N) and 4′,6-diamidino-2-phenylindole (DAPI).
Remdesivir was included as a positive control. The images are representative of the results of three
individual experiments. Scale bar: 1000 µm.
The efficiency of the selected compounds to inhibit SARS-CoV-2 (Figure 3A,B), as well as
their individual effects on cell viability (Figure 3C), cytotoxicity (Figure 3D), and viral titer
were assessed (Figure 3E). The EC50 values for each compound were inferred by calculating the
percentage of virus-infected cells. This indicated that five out of sixteen candidate compounds,
n-nonyldeoxynojirimycin (NN-DNJ), PDNJ0803, chloroquine, Retro-2.1 and URMC-099-C, inhibited
SARS-CoV-2 in a dose-dependent manner (Figure 3C,D). Moreover, these five compounds showed
EC50 values ranging from 0.29 µM to 0.63 µM, without increased cytotoxicity or decreased cell
viability (Figure 3A–D). These results were corroborated by the dose-dependent reduction in viral
titer, where Retro-2.1 displayed the strongest reduction (Figure 3E). Processing the samples at 48 h
post-infection rather than 24 h post-infection showed that the inhibitory effect of all compounds is
reduced at a later phase during infection (Figure S1). The remaining eleven compounds showed little
or no inhibition at lower concentrations and were therefore excluded from further analysis (Figure S2).
In parallel to the inhibition efficiency, the half-maximum cytotoxicity concentration (CC50) was
determined for each compound at concentrations ranging from 0.04 µM to 100 µM on Vero E6 cells.
This demonstrated that the previously tested compounds were all well tolerated at concentrations up
to 100-fold higher than the one used in the initial screen (1 µM) (Figure 3C,D, Appendix B). In contrast,
only URMC-099-C displayed moderate cell cytotoxicity, resulting in a CC50 of 14.7 µM based on viability
and 24.9 µM based on cytotoxicity, while all other compounds had a CC50 above 100 µM (Figure 3C,D,
Appendix B). The resulting selectivity indexes (SI, the CC50-score divided by the EC50-score) showed
that Retro-2.1 (SI = 239.2) is the most efficient and least cytotoxic inhibitor, followed by chloroquine
(SI = 150.8) and URMC-099-C (SI = 50.7). The positive control remdesivir showed a SI of 73.8, while no
SI values were calculated for NN-DNJ and PBDNJ0803 as the EC50-value could not be determined
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(Figure 3B, Appendix B). Combined, these results demonstrate the identification of five compounds of
the pandemic response box library that inhibited SARS-CoV-2 in Vero E6 cells.
Figure 3. Half maximal effective concentration (EC50) determination of the five hit compounds
showing inhibition against SARS-CoV-2. Vero E6 cells were pre-treated for 2 h with the indicated
compound concentrations prior to SARS-CoV-2 infection (MOI 0.01) at 37 ◦C in a humidified incubator
with 5% CO2. Following infection, cells were fixed and processed for immunofluorescence analysis.
To determine the reduction in the percentage of virus-infected cells, the number of cells with a green
fluorescent protein (GFP)-positive cytoplasmic signal (infected cells) was divided by the total number
of cells (DAPI, nuclei). The percentage of virus-infected cells of Retro-2.1 was compared to remdesivir,
DMSO (A) and chloroquine, n-nonyldeoxynojirimycin (NN-DNJ), PBDNJ0803 and URMC-099 (B).
Abbreviations: N.D.: not determined. Results are displayed as means and SD of three independent
experiments. The results of the half-maximum cytotoxicity concentration (CC50) based on viability
(C) or cytotoxicity (D) are shown as means and SD from two individual experiments performed in
two technical replicates. Corresponding supernatants were titrated by tissue culture infectious dose
50 (TCID50) to quantify the log10 reduction in SARS-CoV-2 titer (E). Results are displayed as means and
SD of two independent experiments.
3.3. Inhibition Analysis of SARS-CoV-2 Infection on Calu-3 Cells
To exclude potential cell-specific biases, the previous experiments were additionally performed
using a human lung adenocarcinoma cell line (Calu-3), which recapitulates important biological
aspects of the natural site of infection [26,27]. Interestingly, inhibition of SARS-CoV-2 replication was
only observed upon treatment with Retro-2.1 (EC50: 0.08 µM) or with remdesivir (EC50: 0.17 µM),
based on the percentage of virus-infected cells (Figure 4A,B). The other four compounds showed
no viral inhibition in Calu-3 cells. Determination of the CC50 showed that most compounds were
well tolerated by the Calu-3 cells with values >100 µM, except for URMC-099-C (CC50 = 15.51 µM)
(Figure 4C). Consistently, the percentage of SARS-CoV-2-infected Calu-3 cells treated with Retro-2.1
(SI: 1250) or remdesivir (SI: 588) correlated with viral titers (Figure 4D). This highlights that from the
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five antiviral compounds identified using Vero E6 cells, only Retro-2.1 showed efficient inhibition of
SARS-CoV-2 replication in both Vero E6 and Calu-3 cells.
Figure 4. Analysis of the antiviral efficiency on Calu-3 cells. Calu-3 cells were pre-treated 2 h at the
indicated concentration prior to SARS-CoV-2 infection (MOI 0.02) at 37 ◦C in a humidified incubator
with 5% CO2. Cells were fixed 48 h post-infection, followed by immunostaining with the cross-reactive
SARS-CoV nucleoprotein antibody (SARS N) and DAPI (A). The images are representative of the results
of three individual experiments (only treatments with 4 µM are shown). Scale bar: 1000 µm. The half
maximum inhibitory concentration (EC50) was determined using the percentage of infected cells and
half maximum cytotoxicity concentration (CC50) was determined using cell viability (B, C). Results are
displayed as means and SD of three individual experiments. Abbreviation: N.D.: not determined.
Corresponding log10-reduction in SARS-CoV-2 viral titer for Retro 2.1 and remdesivir treatments (D).
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3.4. Time-of-Addition
To determine which step of the viral replication cycle is affected by Retro-2.1, we performed a
time-of-addition experiment. Confluent Vero E6 cells were either pre-treated with 10 µM of Retro-2.1,
or an equal volume of vehicle control (DMSO), either two hours prior to infection, during infection,
or two hours after infection. Alternatively, Retro-2.1 treatment was performed during both the
pretreatment and virus infection steps (Figure 5A). At 24 h post-infection, the supernatant from
each condition was titrated to determine the infectious viral titer, and the cells were processed for
immunofluorescence analysis as described earlier.
Figure 5. Time-of-addition of Retro-2.1. Time-of-addition was performed by Retro-2.1 treatments pre-,
during and/or post-infection (A). Confluent Vero E6 cells were fixed 24 h post-infection (hpi) followed
by processing for immunostaining with the cross-reactive SARS-CoV nucleoprotein antibody (SARS-N)
and DAPI. The percentage of SARS-CoV-2-infected cells (B) and viral titers in the supernatant (C) were
determined at 24 h post-infection. Graphs show means and SD from three individual experiments,
performed in two technical replicates. (D) Representative images of the indicated conditions. Scale bar:
300 µm.
The most pronounced inhibitory effect was observed when cells were treated with Retro-2.1 after
SARS-CoV-2 infection (condition 3) (Figure 5B,D). In contrast, when cells were treated with Retro-2.1
prior to infection (condition 1), only a marginal reduction was observed. Treatment of cells during
infection (condition 2) showed a more pronounced inhibition, which was comparable to condition 4,
which combines treatment with Retro-2.1 prior and during infection. These results were corroborated
by the viral titers analyzed at 24 h post-infection, demonstrating a >1000-fold reduction in viral titer in
condition 3 (Figure 5C). These data indicate that Retro-2.1 likely interferes with the viral replication
cycle of SARS-CoV-2 during a post-entry step.
4. Discussion
In this study, we have demonstrated that a conservative in vitro screening of 400 compounds from
the PRB using two different cell lines refines the identification of effective antiviral candidate drugs
targeting SARS-CoV-2. The first stage of the screening using Vero E6 cells led to the identification
of five compounds displaying effective antiviral activity against SARS-CoV-2. This included the
anti-malaria drug chloroquine and antibacterial Retro-2.1, as well as the antiviral compounds NN-DNJ,
PDNJ0803, and URMC-099-C. These compounds showed a dose-dependent inhibition of SARS-CoV-2
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infection. However, validation of these selected hits on the human lung cell line Calu-3 revealed that
only Retro-2.1 efficiently inhibited SARS-CoV-2 replication. Time-of-addition analysis showed that
Retro-2.1 likely impairs SARS-CoV-2 replication during a post-entry step of the viral replication cycle.
Combined, these results demonstrate that robust evaluation of novel antiviral candidate drugs should
be performed in different cell lines to exclude potential cell-dependent artefacts. K22, which exerts
a well-documented inhibition of several coronaviruses including SARS-CoV and MERS-CoV, was,
to our knowledge, not tested against SARS-CoV-2 [17,24,25]. Here, we show that K22 did not inhibit
SARS-CoV-2 infection in Vero E6 cells, further emphasizing the requirements of rigorous screening
conditions and robust controls during drug library screening assays.
In the light of the current pandemic, it has become evident that drug repurposing is a promising
strategy that could rapidly help to mitigate SARS-CoV-2 infections. In our study, we employed a
stringent survival screening approach using a library of 400 preselected compounds at a concentration
of 1 µM. Other recent studies have employed different types of libraries and screening conditions,
such as incubation time, cell density and MOI, but alike our study, most employed Vero E6 cells as
an initial screening platform and used remdesivir as a positive control [28,29]. In line with these
studies, we also identified chloroquine, which is approved for clinical use in the context of malaria
treatment, as a potent antiviral compound against SARS-CoV-2, showing the reproducibility of these
screens. Although the evaluation of chloroquine treatments against SARS-CoV-2 infections in clinical
settings has been rapidly undertaken, it has been demonstrated that its antiviral activity on viral entry
is restricted to Vero E6 cells [26]. Concordantly, in our study, we also observed that the impairment of
SARS-CoV-2 replication by chloroquine was restricted to Vero E6 cells. Additionally, limited inhibition
of SARS-CoV-2 by chloroquine was more recently confirmed by experimental infections of Syrian
golden hamsters and rhesus macaques [30]. Altogether, these results emphasize the importance of the
rigorous testing of antiviral compounds in multiple cell lines to exclude potential cell-based artefacts
prior to initiating clinical trials.
In this study, we identified Retro-2.1 as a novel potent compound that inhibited SARS-CoV-2
replication in both Vero E6 and the human lung Calu-3 cell lines. Retro-2.1 has been previously
shown to inhibit a broad range of viruses including enteroviruses, filoviruses, herpes simplex
virus, vaccinia virus and polyomaviruses [31–36]. It has been suggested that Retro-2.1 remodels the
intracellular distribution of syntaxins, which consequently alters vesicular retrograde transport between
endosomes and the Golgi apparatus [37,38]. Moreover, convergent data have reported the strong
dependence on cellular endomembranes and cellular trafficking pathways for efficient coronavirus
replication. Several syntaxins (stxbp1, stxbp3, stx5a, and stx18) were identified in close proximity of
the coronavirus replication and transcription complex during infection, some of which were further
suggested to assist viral replication [39]. Consistent with these studies, our time-of-addition analysis
revealed that Retro-2.1 substantially impairs SARS-CoV-2 infection during a post-entry stage of the
viral replication cycle. Further investigations are required to define the precise molecular targets as
well as the mode of action of Retro-2.1.
In summary, the stringent screening of 400 compounds identified Retro-2.1 as a potent antiviral
compound against SARS-CoV-2 in vitro in different cell lines. This vindicates further efficacy and safety
testing in other biologically relevant pre-clinical in vitro and in vivo models as novel intervention
strategies against SARS-CoV-2 and other coronaviruses.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-2607/8/12/1872/s1.
Figure S1: The EC50 determination of the five top compounds after 48 h of incubation. Figure S2: EC50 determination
of eleven compound hits that showed partial inhibition against SARS-CoV-2.
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Appendix A
Table A1. The sixteen compounds that showed inhibition of SARS-CoV-2 after the survival screen. Remdesivir was included as a reference drug control.
Plate Position: Section MVV-Number CHEMBL ID Reference Name Clinical Stage AccordingCHEMBL Chemical Formula
Plate A, D2 Antifungals MMV1634386 CHEMBL3311228 https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3311228/ Oteseconazole 3 (Phase III) C23 H16 F7 N5 O2
Plate A, E2 Antifungals MMV637528 CHEMBL64391 https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL64391/ Itraconazole 4 (approved) C35 H38 Cl2 N8 O4
Plate B, A2 Antibacterials MMV1483032 CHEMBL243644 https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL243644/ AC1MTT7T 0 (research) C22 H18 N4 O4
Plate B, A7 Antibacterials MMV637945 CHEMBL403 https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL403/ Sulbactam 4 (approved) C8 H11 N O5 S
Plate B, D9 Antibacterials MMV1582492 CHEMBL3109593 https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3109593/ Retro-2.1 0 (research) C23 H18 F N3 O S2
Plate B, F3 Antibacterials MMV1582487 CHEMBL198796 https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL198796/ Decylphosphinate 0 (research) C13 H28 N O4 P
Plate C, A5 Antibacterials MMV1578576 CHEMBL1568820 https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1568820/ - 0 (research) C15 H12 F N3 O
Plate C, E7 Antibacterials MMV000008 CHEMBL76 https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL76/ Chloroquine 4 (approved) C18 H26 Cl N3
Plate D, A11 Antivirals MMV1593513 CHEMBL408500 https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL408500/
N-Nonyl
Deoxynojirimycin
(NN-DNJ)
0 (research) C15 H31 N O4
Plate D, C7 Antivirals MMV690621 - Patent: WO2006118607A2 NA for racemic - C18 H16 Cl N3 O
Plate D, E10 Antivirals MMV1634401 CHEMBL1652119 https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1652119/ PBDNJ0803 0 (research) C20 H33 N O5
Plate D, E11 Antivirals MMV002780 CHEMBL402487 https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL402487/ Noscapine 0 (research) C22 H23 N O7
Plate E, A6 Antivirals MMV1580482 CHEMBL2436978
https://www.ebi.ac.uk/chembl/compound_
report_card/CHEMBL2436978/
Patent: WO 2014085795 A1
URMC-099-C 0 (research) C27 H27 N5
Plate E, B7 Antivirals MMV1593544 CHEMBL3752642 https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3752642/ - 0 (research) C36 H43 N3 O5
Plate E, E11 Antifungals MMV002350 CHEMBL561 https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL561/ Lomefloxacin 4 (approved) C17H19F2N3O3
Plate E, F11 Antivirals MMV1580483 CHEMBL3960662 https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3960662/ AZD0156 0 (research) C26 H31 N5 O3
- Control - CHEMBL4065616 https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4065616/ Remdesivir 2 (Phase II) C27 H35 N6 O8 P
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Appendix B
Table A2. The EC50, EC90 and CC50 values of the five compounds that showed inhibition of SARS-CoV-2 during the compound dilution series on VeroE6-cells,
including references to the mode of action of these compounds against other viruses. Remdesivir is included as a reference drug control. Abbreviations: N.D.:
not determined.
Compound EC50 in µM EC90 in µM CC50 in µM
Selective
Index (SI) Class
Examples of
Susceptible Viruses
Literature
Reference Mode of Action Administration
Tested on Cells
or Organism Molecular Structure
Retro-2.1 0.418 1.03 100 239.2
Retrograde
transport
inhibitor
• Enterovirus
• Herpes simplex virus
• Filoviruses
• Vaccina virus
• Polyomavirus
[31–36]
• Modulate intracellular
vesicle transport
(Enterovirus 71),
• Blocks entry (Herpes
Simplex Virus 2)
• Blocks entry that
follows by glycoprotein
proteolysis (Filoviruses)
• Localization towards the
ER (Polyomavirus)
• endosome-to-Golgi
apparatus trafficking
(Vaccina virus)
• induce cellular STX5
displacement from the
Golgi upon treatment,
leading to an inhibition
of retrograde transport
(Cytomegalovirus)
• Prophylactic
• Therapeutic
• Vero
• HeLa
• 293S
• Mice
Chloroquine 0.663 10.44 100 150.82
Autophagic
proteolysis
inhibitor
Endosomal
acidification
inhibitor
• Herpes simplex virus
• Picornaviruses
• Poliovirus
• SARS-CoV
• HIV-1
• Hepatitis A virus
• Hepatitis B virus
• Hepatitis C virus
• Influenza A virus
• Influenza B virus
• Bovine viral
diarrhea virus
• 229E-CoV
• OC43-CoV
• Chikungunya virus
• Dengue virus
• Crimean-Congo
Hemorrhagic fever
• Ebola virus
• Nipah virus
• Hendra virus
• Lassa virus
• Rabies virus
[40–62]
• Raise endosomal
pH (Picornavirus)
• Terminal glycosylation
of the ACE2-receptor
(SARS-CoV)
• Alter the glycosylation of
the glycoprotein (HIV-1)
• Interference with
endosomal acidifcation
(Hepatitis C virus)
• Endosomal acidification
(BVDV)
• P38 MAPK and ERK
activation (229E)
• Prophylactic
• Therapeutic
• VeroE6
• Vero 76
• L132
• MDBK
• Huh7
• NS20 murine
• neuroblastoma cells
• B-SC-1
• A549
• Humans
• U937
• MRC5
• Guinea pigs
Microorganisms 2020, 8, 1872 14 of 19
Table A2. Cont.
Compound EC50 in µM EC90 in µM CC50 in µM
Selective
Index (SI) Class
Examples of
Susceptible Viruses
Literature
Reference Mode of Action Administration
Tested on Cells
or Organism Molecular Structure
N-Nonyl
Deoxyno
Jirimycin
(NNDNJ)
N.D. N.D. 100 N.D.
ER
α-glucosidase
inhibitors
• Bovine viral
diarrhea virus
• West nile virus
• Dengue virus
• Hepatitis B virus
• Hepatitis C virus
• Flaviviruses
• Woodchuck
hepatitis virus
• Ebola virus
• Tacaribe virus
• Junin virus
• SARS-CoV
[63–71]
US patent:
9040488
• Protein folding
(Hepatitis B virus, Bovine
viral diarrhea virus)
• Protein trafficking
(Woodchuck
hepatitis virus)
• Prophylactic
• Therapeutic
• MDBK
• BHK (-21)
• HepG2
• Huh7.5
• Woodchucks
PBDNJ0803 N.D. N.D. 100 N.D.
ER
α-glucosidase
inhibitors
• Dengue virus
• Bovine viral
diarrhea virus
• West nile virus
• Ebola virus
• Tacaribe virus
• Junin virus
[69,70]
US Patent:
9040488
• Protein folding (Bovine
viral diarrhea virus) • Therapeutic
• MDBK
• BHK
• Vero
URMC-099-C 0.29 1.83 14.7 50.69
Mixed-lineage
kinase 3
inhibitor
• HIV-1
• Zika virus [72–75]
• Anti-inflammatory
• Blocks phosphorylation
of MLK3
• Inhibits viral maturation
in the endosome
• pro-viral effect
in replication
• Prophylactic
• Therapeutic
• BV-2 microglial
• Mice
• Macrophages
• SNB-19
Remdesivir 1.354 3.39 100 73.85 Nucleosideanalogue
• Ebola virus
• Marburg virus
• SARS-CoV
• MERS-CoV
• Respiratory
Syncitial Virus
• Junin virus
• Lassa virus
• Hendra virus
• Nipah virus
• Rift Valley
Fever Virus
• Mumps virus
• Measles virus
• Coronaviruses
• Murine
hepatitis virus
[18,76–80]
• Interferes with the
RNA dependent RNA
polymerase activity
• Prophylactic
• Therapeutic
• Primary
macrophages
• HeLa
• HFF-1
• HMVEC-TERT
• Rhesus monkeys
• Huh7
• Hep-2
• U2OS
• Vero
• Mice
• Human
airway epithelial
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